Amylyx Pharmaceuticals, Inc. (AMLX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Amylyx Pharmaceuticals reported revenue of $0, down 100.0% from $87.4M the year before. Net income was -$144.7M, or -$1.53 per diluted share. Operating activities generated -$123.3M of cash, leaving -$123.5M of free cash flow. At fiscal year end, Amylyx Pharmaceuticals held $332.6M in total assets against $27.4M in total liabilities, including $226.7M of cash and equivalents.
Open the full interactive Amylyx Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Amylyx Pharmaceuticals Key Stats
| Share Price | $26.85 |
|---|---|
| Market Cap | $2.99B |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $11.38 – $39.66 |
| Shares Outstanding | 111.2 million (basic, 2026 Q2) |
Amylyx Pharmaceuticals Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $22.2M | $380.8M | $87.4M | $0 |
| Cost of Goods Sold | $3.0M | $25.4M | $6.0M | $0 |
| Gross Profit | $19.2M | $355.3M | $81.4M | $0 |
| Operating Income | -$201.3M | $38.8M | -$314.7M | -$153.3M |
| Pre-Tax Income | -$197.6M | $54.3M | -$302.1M | -$144.7M |
| Income Tax | $774,000 | $5.0M | -$393,000 | $46,000 |
| Net Income | -$198.4M | $49.3M | -$301.7M | -$144.7M |
| Diluted EPS | -$3.39 | $0.70 | -$4.43 | -$1.53 |
Amylyx Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$34.4M | -$33.0M | -$41.3M | -$43.4M |
| Diluted EPS | -$0.37 | -$0.35 | -$0.37 | -$0.39 |
Amylyx Pharmaceuticals Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $62.5M | $170.2M | $77.4M | $226.7M |
| Current Assets | $382.1M | $464.7M | $189.4M | $323.7M |
| Total Assets | $391.5M | $517.5M | $193.6M | $332.6M |
| Current Liabilities | $46.6M | $82.0M | $28.4M | $22.7M |
| Total Liabilities | $50.8M | $84.0M | $28.9M | $27.4M |
| Shareholders' Equity | $340.6M | $433.4M | $164.8M | $305.3M |
Amylyx Pharmaceuticals Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$179.9M | $11.9M | -$167.6M | -$123.3M |
| Cash From Investing | -$239.0M | $92.1M | $75.7M | $14.0M |
| Cash From Financing | $431.8M | $3.5M | $348,000 | $257.0M |
| Free Cash Flow | -$182.4M | $10.7M | -$167.8M | -$123.5M |
Figures from Amylyx Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Amylyx Pharmaceuticals financials page for every line item.
Amylyx Pharmaceuticals Company Profile
| Ticker | AMLX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001658551 |
Frequently Asked Questions
What was Amylyx Pharmaceuticals' revenue in fiscal 2025?
Amylyx Pharmaceuticals (AMLX) reported revenue of $0 for fiscal 2025.
What is Amylyx Pharmaceuticals' annual revenue history?
Amylyx Pharmaceuticals' annual revenue by fiscal year: 2022: $22.2M; 2023: $380.8M; 2024: $87.4M; 2025: $0.
What was Amylyx Pharmaceuticals' net income in fiscal 2025?
Amylyx Pharmaceuticals reported net income of -$144.7M for fiscal 2025.
What was Amylyx Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Amylyx Pharmaceuticals' diluted EPS was -$1.53 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Amylyx Pharmaceuticals generate in fiscal 2025?
Amylyx Pharmaceuticals generated -$123.5M of free cash flow in fiscal 2025.
What was Amylyx Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Amylyx Pharmaceuticals reported revenue of $0.
How many shares of Amylyx Pharmaceuticals are outstanding?
Amylyx Pharmaceuticals reported a weighted average of 111.2 million basic shares outstanding in 2026 Q2.
What is Amylyx Pharmaceuticals' market cap?
Based on its latest closing price, Amylyx Pharmaceuticals (AMLX) has a market capitalization of about $2.99B.
When does Amylyx Pharmaceuticals' fiscal year end?
Amylyx Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Amylyx Pharmaceuticals headquartered?
Amylyx Pharmaceuticals lists its business address in Cambridge, Massachusetts in its SEC filings.